Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarterfool.comAlumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases through proprietary TYK2 inhibitors.
Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rallyfool.comThis clinical-stage biotech develops antibody therapies for severe autoimmune diseases, targeting rare neuromuscular conditions.
Erasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million Morefool.comThis clinical-stage biotech targets RAS/MAPK pathway cancers with a pipeline of novel small molecule oncology therapies.
Bicara Stock Is Up 50%, and One Biotech Investor Has Made It a 29% Portfolio Betfool.comThis clinical-stage biotech develops bifunctional antibody therapies targeting solid tumors for oncology providers and institutions.
Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Backfool.comAlumis Inc. develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases using allosteric TYK2 inhibitors.
Kestra Medical Grew Revenue 63%. One Fund Still Trimmed 351,000 Sharesfool.comKestra Medical Technologies develops advanced wearable cardiac devices and digital health solutions for cardiovascular care providers.
This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know?fool.comThis biotech develops Nanobody-based therapies targeting chronic inflammatory diseases in dermatology and rheumatology markets.
This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Dealfool.comArcellx develops cell-based immunotherapies for cancer, leveraging proprietary platforms to address high unmet needs in oncology.
Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launchfool.comOlema Pharmaceuticals develops targeted therapies for women's cancers, with a lead candidate in clinical trials for breast cancer treatment.
This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarterfool.comPraxis Precision Medicines develops clinical-stage therapies for neurological disorders, targeting major unmet needs in CNS therapeutics.
